Want to join the conversation?
$LRCX 4Q15 Call: In the DRAM segments markets' demand continues to be driven by mobile and enterprise DRAM growth. DRAM investments, which as we have said are biased for the first half of calendar 2015 are very efficient and focus primarily on technology conversions to 20-nanometer.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.